Two questions account for most of what people want to know about estradiol cypionate. How much, how often. And how it stacks up against estradiol valerate, the other oil-based injectable estradiol ester that shows up in the same conversation.
The approved labeling answers both, though not always in the way the internet reports it. For moderate to severe vasomotor symptoms the usual range is 1 to 5 mg every 3 to 4 weeks. On the comparison, the two esters separate far less on how long they last than on concentration, oil vehicle and what each one is actually labeled to treat.
What Is Estradiol Cypionate?
Chemically it is estradiol 17-cyclopentanepropionate. Practically, it is 17β-estradiol with a fatty side chain attached and the whole thing dissolved in oil, which is what slows its exit from the injection site.
That slowness is the point. A hormone that clears in hours needs daily dosing. Attach the ester, suspend it in oil, and one injection covers an interval measured in weeks. Everything else about the product follows from that single design decision, including how it is stored, why it can crystallize and why a missed dose behaves differently than it would with a daily tablet.
Is It Bioidentical?
For the hormone, yes. The estradiol released from the ester is structurally identical to the 17β-estradiol the body makes, and the cypionate group is a carrier that gets cleaved off after injection.
The vial itself is a different matter, because what is sitting in it is the esterified form rather than free estradiol. Both statements are true at once, which is why the question generates so much confusion. MediVera prepares bioidentical hormone formulations under prescription for individual patients.
How Long Does It Last?
Here the honest answer is less satisfying than the ones circulating. The approved labeling for this ester publishes no half-life value at all, and its public chemical record does not carry one either.
What the labeling does say is that a single intramuscular injection of an oil-based estradiol ester is absorbed over several weeks, and the labeled intervals were built around that. Any specific figure quoted online came from somewhere other than the label, which is worth knowing before someone plans a dosing interval around it.
Estradiol Cypionate vs. Estradiol Valerate
This is the question that comes up more than any other, and a lot of what gets repeated in answer to it does not survive a look at either label. So the table below reports only what the FDA-approved prescribing information for each ester states.
| Attribute | Cypionate ester | Valerate ester |
|---|---|---|
| Chemical name | Estradiol 17-cyclopentanepropionate | Estra-1,3,5(10)-triene-3,17-diol(17)-, 17-pentanoate |
| Labeled concentration | 5 mg/mL | 10 mg/mL, 20 mg/mL and 40 mg/mL |
| Oil vehicle | Cottonseed oil, 913 mg per mL | Sesame oil at 10 mg/mL; castor oil at 20 mg/mL and 40 mg/mL |
| Preservative | Chlorobutanol, 5.4 mg per mL | Chlorobutanol at 10 mg/mL; benzyl alcohol with benzyl benzoate at the higher strengths |
| Labeled route | Intramuscular only | Intramuscular, deep into the upper outer quadrant of the gluteal muscle |
| Vasomotor symptom dosing | 1 to 5 mg every 3 to 4 weeks | 10 to 20 mg every four weeks |
| Hypogonadism dosing | 1.5 to 2 mg at monthly intervals | 10 to 20 mg every four weeks |
| Number of labeled indications | Two | Four |
| Storage | 20 to 25 °C controlled room temperature | 20 to 25 °C controlled room temperature |
| Published half-life | Not stated in labeling | Not stated in labeling |
Duration of Action, and What the Labeling Actually Says
The claim you will meet most often is that cypionate runs 3 to 6 weeks and valerate runs 2 to 3. Neither number is in either label.
The labels use one phrase for both, saying that a single intramuscular injection of estradiol valerate or estradiol cypionate is absorbed over several weeks. So the labeled intervals sit closer together than the received wisdom suggests. Cypionate goes every 3 to 4 weeks for vasomotor symptoms and monthly for hypogonadism, valerate every four weeks across all of its indications.
Where they genuinely part company is dose size. Valerate is labeled at 10 to 20 mg. Cypionate is labeled at 1 to 5 mg, which is a four-fold to twenty-fold difference depending on which end of each range you take, and it is a far more useful thing to know than a duration figure nobody can source.
Oil Vehicle and Concentration
The vehicle is not trivia. It drives injection comfort, the needle gauge that works, the volume going into the muscle and, occasionally, whether a patient can receive the product at all.
Cypionate comes one way, 5 mg/mL in cottonseed oil. Valerate comes three ways, sesame oil at its lowest strength and castor oil at the two above it, running four to eight times more concentrated.
Preservatives split the same way. Chlorobutanol in the cypionate product, benzyl alcohol with benzyl benzoate in the stronger valerate presentations. A documented sensitivity to sesame, cottonseed or benzyl alcohol turns all of this from a formulation footnote into the deciding factor, and it is one of the situations in which a prescriber may determine that no commercially available presentation is suitable for a particular patient.
Switching Between the Two Esters
People ask for a conversion ratio. There is not one in either label.
No milligram-for-milligram equivalence, no switching protocol, no washout interval. Any conversion figure in circulation came out of clinical practice rather than an approved source, which does not make it wrong but does change what it is.
What the labels do give is a starting point for each product on its own terms. A prescriber moving a patient between esters is choosing a fresh regimen from the new product’s labeling rather than translating the old one across. In practice the vehicle, the available strengths and the injection volume tend to weigh as heavily as the milligrams.
Where Estradiol Enanthate Fits
Estradiol enanthate keeps turning up as a third option in these comparisons. It does not really belong there, at least not in the United States, where no standalone single-agent injectable enanthate product carries FDA approval.
Comparisons that line it up beside cypionate and valerate as an interchangeable alternative are describing compounded or non-US preparations. Worth naming before anyone plans an interval around it.
How It Works and What It Is Approved to Treat
Estradiol is the principal intracellular human estrogen. Before menopause the ovarian follicle supplies most of it; afterward most of it comes from peripheral conversion of adrenal androstenedione.
Estrogens as a class bind nuclear receptors in estrogen-responsive tissue and dial down pituitary secretion of luteinizing hormone and follicle stimulating hormone through negative feedback. That mechanism belongs to the estradiol molecule, not to any particular preparation of it. The distinction matters more than it sounds like it should.
The Two Labeled Indications
The FDA-approved prescribing information for the cypionate injection lists two indications. Two, not four.
- Moderate to severe vasomotor symptoms associated with menopause.
- Hypoestrogenism due to hypogonadism.
If you have seen a longer list attached to this ester, including genitourinary syndrome of menopause, primary ovarian insufficiency or Turner syndrome, it belonged to a different product. The valerate labeling does carry four indications, adding vulvar and vaginal atrophy and advanced androgen-dependent prostate carcinoma. Two labels, similar molecules, easy mistake, and it has propagated widely.
Use Outside the Labeled Indications
Off-label use of this drug exists in clinical practice, feminizing hormone therapy among it. That is a prescriber decision made for an individual patient and it sits outside what the labeling supports.
MediVera does not publish dosing guidance for unlabeled uses. Those protocols belong with the treating clinician, full stop.
Dosing and Injection Schedule
Everything below comes from the approved prescribing information. Dosing decisions belong to the prescriber. The labeling directs that estrogen therapy be given at the lowest dose that meets the treatment goal, for the shortest duration consistent with the goals and risks for that individual patient.
Intramuscular Dosing by Indication
- Moderate to severe vasomotor symptoms of menopause. The usual dosage range is 1 to 5 mg injected every 3 to 4 weeks.
- Female hypoestrogenism due to hypogonadism. 1.5 to 2 mg injected at monthly intervals.
Reassessment and Discontinuation
The labeling asks for reevaluation at clinically appropriate intervals and offers 3 to 6 months as its example. For short-term cyclic use in vasomotor symptoms it goes a step further, instructing that attempts to discontinue or taper be made at those same 3 to 6 month intervals. Continuation is meant to be a decision, not a default.
One requirement travels alongside the dosing and gets missed more often than the dosing itself. When an estrogen is prescribed for a woman who has a uterus, a progestin should also be initiated to reduce the risk of endometrial cancer. A woman without a uterus does not need progestin.
Intramuscular vs. Subcutaneous Administration
The approved labeling restricts estradiol cypionate injection to intramuscular use, and it says so in capital letters. No separate subcutaneous product is described anywhere in that labeling. The word subcutaneous does not appear in it at all.
That last detail is worth sitting with, because subcutaneous administration of oil-based estradiol esters is genuinely described in clinical practice and in published literature. Both things are true. It is a real practice and an unlabeled route, not an approved presentation of the drug, and anyone weighing it should treat it as a prescriber decision made with that gap in full view.
Injection Technique for the Labeled Route
- Look at the vial first. Parenteral products should be checked visually for particulate matter and discoloration whenever the solution and container permit.
- Crystals are not spoilage. Storage below the recommended temperature can precipitate them, and warming with agitation puts them back into solution.
- Deep into muscle. Oil-based estrogen injections go intramuscularly, following the usual precautions for that route.
- Dry needle, dry syringe. Moisture will cloud an oil solution, which is a small thing that looks alarming when it happens.
How injections compare with creams, pellets and the other routes is a longer conversation, covered in our guide to BHRT delivery methods and the overview of compounded hormone creams.
Formulation, Storage and Safety
These specifications describe the commercially available product. A compounded preparation is made to an individual prescription, so its concentration, vehicle and beyond-use dating come from that prescription and the applicable compounding standards rather than from the figures below.
Product Specifications
- Concentration. 5 mg of estradiol cypionate per mL.
- Vehicle. 913 mg of cottonseed oil per mL.
- Preservative. 5.4 mg of chlorobutanol anhydrous per mL, which carries a labeled warning that chlorobutanol may be habit forming.
- Presentation. 5 mL multiple-dose vial.
- Appearance. A clear oil solution, inspected before each use.
A 10 mg/mL strength turns up in search results and in veterinary supply, and it is not the concentration of the commercially manufactured human product. A compounded preparation carries whatever concentration its prescription specifies. Either way the strength on the vial gets checked against the prescription, because a twofold difference at these dose levels is not a rounding error.
Storage and Beyond-Use Dating
Controlled room temperature, 20 to 25 °C or 68 to 77 °F. Refrigeration is not called for, and cold storage is exactly what produces the crystallization the labeling describes. A compounded preparation runs on the beyond-use date assigned when it was prepared, which governs it rather than any manufacturer expiry.
Side Effects and Safety Considerations
Estrogen therapy carries boxed warnings covering endometrial cancer, cardiovascular disorders and probable dementia. Beyond those, reported effects run to injection-site reactions, breast tenderness, nausea, headache and irregular vaginal bleeding, most of them familiar to anyone who has managed estrogen therapy before.
Estrogens are contraindicated in undiagnosed abnormal genital bleeding, known or suspected breast cancer or estrogen-dependent neoplasia, active or recent thromboembolic disease, liver dysfunction and known or suspected pregnancy. New or recurring abnormal vaginal bleeding gets evaluated rather than watched, and the labeling calls for diagnostic measures such as endometrial sampling to rule out malignancy in women who have a uterus.
Insurance and Out-of-Pocket Considerations
Coverage for compounded preparations works differently than coverage for commercially manufactured products. Many plans process them under separate rules, some not at all, so a plan-specific answer is worth having before the first fill. Health savings and flexible spending accounts are commonly usable. Our overview of insurance coverage for bioidentical hormone therapy and the breakdown of hormone replacement therapy cost walk through the mechanics.
Frequently Asked Questions
What does estradiol cypionate do?
It delivers estradiol from an oil depot in the muscle across a period of weeks. The released estradiol binds nuclear estrogen receptors in responsive tissue and brings down the elevated gonadotropin levels that appear when endogenous estrogen is low. Its labeled uses are moderate to severe vasomotor symptoms of menopause and hypoestrogenism due to hypogonadism.
What is the difference between estradiol cypionate and estradiol valerate?
Different esters of the same hormone. Cypionate is labeled at 5 mg/mL in cottonseed oil, dosed at 1 to 5 mg every 3 to 4 weeks. Valerate is labeled at 10, 20 and 40 mg/mL in sesame or castor oil, dosed at 10 to 20 mg every four weeks.
Both labels describe absorption over several weeks and neither publishes a duration figure. So the real differences are concentration, oil vehicle, dose size and labeled indication rather than how long each one lasts.
Where is estradiol cypionate injected?
Intramuscularly. That is what the approved labeling permits, given deep into muscle with the usual precautions for the route. Since the word subcutaneous never appears in the labeling for this product, any subcutaneous administration is an unlabeled route and a prescriber decision.
Can estradiol cypionate be injected subcutaneously?
Not under its approved labeling, which specifies intramuscular use only. The practice does exist and is described in published literature, so the accurate answer is that it happens off-label rather than that it never happens. That decision belongs with the treating clinician.
How often is estradiol cypionate injected?
Every 3 to 4 weeks for moderate to severe vasomotor symptoms, monthly for female hypoestrogenism due to hypogonadism. The labeling also asks for reevaluation at intervals such as every 3 to 6 months to confirm continued treatment is still warranted.
What is the half-life of estradiol cypionate?
The approved labeling does not publish one, and neither does the compound’s public chemical record. What the labeling states is that a single intramuscular injection of an oil-based estradiol ester is absorbed over several weeks, and the labeled 3 to 4 week interval reflects that. Figures quoted elsewhere trace back to neither source.
Is estradiol cypionate bioidentical?
The estradiol it releases is structurally identical to the 17β-estradiol the body produces. The contents of the vial are the esterified form, with a cypionate group attached as a carrier that gets cleaved off after injection to release the estradiol.
How should estradiol cypionate be stored?
Controlled room temperature, 20 to 25 °C or 68 to 77 °F. Colder than that and crystals can form in the oil, which warming the vial with agitation reverses. A compounded preparation runs on the beyond-use date assigned when it was prepared.
Can you get estradiol cypionate in the United States?
Yes, with a prescription from a licensed prescriber. A commercially manufactured intramuscular product is available, and a licensed pharmacy may prepare a compounded version when the commercial product is unavailable or unsuitable for a specific patient.
Prescribing Through MediVera
Compounding starts where the commercial presentation stops. That might be a documented sensitivity to the oil vehicle or the preservative, or a concentration the single commercial strength cannot give. MediVera prepares compounded hormone formulations to an individual prescription for those situations.
Compounded medications are not reviewed by the FDA for safety or effectiveness, and are prepared under a licensed prescriber’s order and are not intended to replace FDA-approved therapies.
Prescribers can send a prescription or open an account through our provider services. MediVera holds PCAB accreditation and sources active ingredients from FDA-registered suppliers, with the specifics in our quality and compliance standards. The wider service sits under hormone replacement therapy compounding.
References
- DailyMed structured product labeling, estradiol cypionate injection
- FDA prescribing information, estradiol cypionate injection
- FDA prescribing information, estradiol valerate injection USP
- PubChem compound record for the cypionate ester (CID 9403)
- ClinicalKey pharmacology monograph, estradiol
- Drugs.com drug information, estradiol
